BIO-RAD LABORATORIES, INC. (NYSE:BIO) Files An 8-K Other Events

BIO-RAD LABORATORIES, INC. (NYSE:BIO) Files An 8-K Other Events
Item 8.01Other Events

Story continues below

On November 28, 2017, Bio-Rad Laboratories, Inc. (the “Company”) announced that its board of directors authorized a new share repurchase program, granting the Company authority to repurchase, on a discretionary basis, up to $250 million of the outstanding shares of the Company’s common stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Any shares acquired will be available for general corporate purposes, including supporting employee stock plans, funding acquisitions and minimizing dilution from stock issuances. This new share repurchase program supersedes the Company’s prior share repurchase program.

A copy of the press release announcing this action is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01Financial Statements and Exhibits.


BIO RAD LABORATORIES INC Exhibit
EX-99.1 2 bio-8k11292017xex991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1PRESS RELEASE Bio-Rad Authorizes New $250 Million Share Repurchase Program HERCULES,…
To view the full exhibit click here

About BIO-RAD LABORATORIES, INC. (NYSE:BIO)

Bio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of life science research and clinical diagnostics products. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. Bio-Rad operates in two segments: Life Science and Clinical Diagnostics. The Company’s Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. The Company’s Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. Bio-Rad sells over 8,000 products and services to a client base consisting of scientific research, healthcare, education and government customers around the world.

An ad to help with our costs